DualityBio

Our Vision: To Translate Novel Modality into Reality

DualityBio is a clinical stage company focusing on the discovery and development of the next generation ADC therapeutics to treat patients in cancer and autoimmune diseases. Leveraging on the decades of learning, we have successfully established a number of next-generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights.

These include DITAC (Duality Immune Toxin Antibody Conjugate) with significantly improved therapeutic window and DIMAC (Duality Immune Modulating Antibody Conjugate) with superior efficacy than traditional biologics. Built upon our deep understanding of disease biology and translational capability, we have built a robust pipeline of more than 10 best-in-class and/or first-in-class ADC programs with the potential to make a life changing difference for patients. Additionally, we are continuing evolving our protein engineering and ADC technology for the next wave of “super ADC” molecules including diverse payload class, bispecific ADC and dual payload ADC to further harness the potential of ADC modality.

The company was founded in January 2020 by Dr. John Zhu, a seasoned company builder in the healthcare industry and led by an experienced management team with proven track record in discovering and developing novel medicines for global market. We are currently operating in both China and United States.